Patent ID: 8124353
Filing Date: 2012-02-28
Classification: A61K,A61P,C07K,G01N

Abstract:
1. A method for monitoring minimal residual disease in a patient following treatment with a pharmaceutical composition which comprises a humanized antibody or a fragment thereof that specifically binds to β-amyloid protein, wherein said method comprises: a. bringing a sample suspected to contain β-amyloid antigen into contact with a humanized antibody or a fragment thereof which specifically binds β-amyloid protein, wherein said humanized antibody or fragment thereof comprises a Light Chain Variable Region (LCVR) comprising SEQ ID NO:12 and a Heavy Chain Variable Region (HCVR) comprising SEQ ID NO:15; b. allowing the humanized antibody or fragment thereof to bind to β-amyloid antigen to form an immunological complex; c. detecting the formation of the immunological complex; d. correlating the presence or absence of the immunological complex with the presence or absence of amyloid antigen in the sample; and e. comparing the amount of said immunological complex to a normal control value, wherein an increase in the amount of said immunological complex compared to a normal control value indicates that said patient still suffers from a minimal residual disease.